BU-NOT-SET

CONTACT US
The role of excipient selection in the development of orally disintegrating tablets
  • Drug product
Eyes
Insight
The outlook for a year of change
  • Industry trends
Eyes
Insight
Can oral solid dose keep its place as the leading dosage form?
  • Drug product
Eyes
Insight
Relocating API supply to avoid over-reliance
  • Drug substance
Eyes
Insight
Modified release fixed dose combination product with two poorly soluble drug substances
  • Drug product
pellets
Case study
Patient centricity during drug development and commercialisation
  • Drug product
Eyes
Insight
10 considerations to kick-start your drug development journey
  • Drug product
Eyes
Insight
Guidance for start-ups on drug development
  • Drug product
Eyes
Insight
Drug development for start-ups
  • Drug product
  • Drug substance
Test tubes
White paper
Insight
  • Biologics
Innovation & leadership across the advanced therapy space
Insight
  • Biologics
Overcoming oncolytic virus obstacles with the help of a CDMO partnership
Webinar
  • Biologics
Webinar: Beyond borders: Navigating global scale-up for viral-based therapies
eBook
  • Drug product
Choosing the right container for your sterile drug product
White paper
  • Biologics
Cell and virus banking in OV development and manufacturing
Insight
  • Biologics
Overcoming technical transfer challenges in virotherapy manufacturing
eBook
  • Biologics
Flexibility in gene therapy: Adapting to the unique gene therapy demands
Webinar
  • Biologics
Webinar: An optimised Plasmid DNA platform
Insight
  • Drug substance
  • Industry trends
The future of oral solid dose formulations